Gleevec for sale in India Gleevec purchase Gleevec price 18311393889

' ' Generic name Imatinib mesylate (produced by an Indian company. Commonly known as Indian Gleevec) Scientific name English name Specifications Tablets/bottle Chinese Pinyin Because it is produced by an Indian company, it has not been approved by the Food and Drug Administration in China, so in China Drugs are illegal in China and this encyclopedia is for annotation purposes only. The following introduction is an introduction to Gleevec, not an introduction to it. Gleevec in India is a common name for uninformed users.
, ) ' ' , ) )
, ) Gleevec (imatinib mesylate) is a new generation of targeted inhibitory effect on platelet-derived growth factor receptor protein kinase Sexual anticancer drugs. Gleevec is the most effective of all anti-tumor drugs. The effective rate of Gleevec in the treatment of newly diagnosed chronic myelogenous leukemia exceeds 1%, and % of patients can achieve cytological remission.
, ) ' '
, ) ' 'br/> , )
, ) //
, )
, )
, )
, )
, )
, ) , ) ) Gleevec (imatinib mesylate) is packaged as tablets per bottle, and each tablet contains. Imatinib mesylate, equivalent of imatinib free base. Medicines are packaged in white polyethylene bottles.
, )
, ) The results of phase III clinical trials show that Gleevec is more than 50% effective in the treatment of newly diagnosed chronic myelogenous leukemia, and % of patients can achieve cytological remission. The effective rates during the acceleration period and the acute change period also reached % and % respectively. The effective rate of Gleevec against gastrointestinal stromal tumors is also as high as %.
, )
, ) Indications
, )
, ) Gleevec (imatinib mesylate) for the treatment of newly diagnosed Philadelphia chromosome positive (+) of adult chronic myelogenous leukemia in the chronic phase.
, )
, ) Gleevec (imatinib mesylate) is used to treat Philadelphia chromosome-positive chronic myelogenous leukemia in blast phase and accelerated phase. Imatinib mesylate It is also used to treat chronic myelogenous leukemia in the chronic phase that has been treated with interferon.
, )
, ) Gleevec (imatinib mesylate) is also used to treat pediatric chronic myelogenous leukemia that has relapsed after myelosuppression or has failed to respond to interferon therapy.
, )
, ) Gastrointestinal stromal tumor
, )
, ) Gleevec (imatinib mesylate) is used to treat positive inoperable or Metastatic malignant gastrointestinal stromal tumor
, )
, ) Main toxic and side effects The most common toxic and side effects include superficial edema, malignancy and vomiting, muscle aches, muscle spasms, rash and diarrhea.
, )
, ) Hematologic toxicities, including neutropenia and thrombocytopenia, are common side effects of Gleevec (imatinib) treatment, but they occur in newly diagnosed CML patients. lower.
, )
, ) Gleevec is an indication approved by the Mainland Food and Drug Administration for the treatment of the chronic phase, accelerated phase or blast phase of Philadelphia chromosome-positive chronic myelogenous leukemia (+). For the treatment of chronic, accelerated or blast phase of Philadelphia chromosome-positive chronic myelogenous leukemia (+)
, )
, ) for the treatment of unresectable and/or metastatic malignant gastrointestinal tract The safety and effectiveness information for the following indications in adult patients with stromal tumors mainly comes from foreign research data. Data on the Chinese population are limited. It is used for the treatment of adults with relapsed or refractory Philadelphia chromosome-positive acute lymphoblastic leukemia (+). For the treatment of adult patients with hypereosinophilic syndrome and/or chronic eosinophilic leukemia with fusion kinase. Imatinib mesylate is the world's first approved tumorigenesis-related signaling inhibitor for chronic myelogenous leukemia and gastrointestinal stromal tumors. Treatment should be initiated initially by a physician experienced in treating chronic myelogenous leukemia. The recommended dose of imatinib mesylate for patients in the blast phase and accelerated phase is /day, and for patients in the chronic phase who have failed interferon treatment, it is /day. Both are taken orally once a day. It is advisable to take the medicine with a meal and drink it once a day. A large glass of water and should be continued for as long as it is effective. If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from / day to / day, or from / day to / day (oral)
, )
, ) Usage Dosage Edit Starting dose For patients with chronic myelogenous leukemia in the blast phase and accelerated phase, the recommended dose of imatinib mesylate is/day. For patients in the chronic phase who have failed interferon therapy, as well as patients with malignant gastrointestinal cancer that cannot be surgically removed or metastasized. For patients with stromal tumors, the recommended dose is 1/day, which should be taken orally once a day. It is advisable to take the medicine with meals and drink a large glass of water. As long as it is effective, it should be continued.
, )
, ) If the blood picture permits and there are no serious adverse drug reactions, the dose may be considered to be increased from / day to / day, or from / day to / day ( , taken in divided doses ) The disease progresses and a satisfactory hematological response fails to be obtained after at least three months of treatment, and the hematological response that has been achieved disappears again.
, )
, ) The dose must be adjusted in the following situations. If serious non-hematological adverse reactions (such as severe water retention) occur during treatment, it is advisable to discontinue the drug until the adverse reactions disappear, and then resume treatment based on the adverse reactions. Adjust dose according to severity of reaction.
, )
, ) Dosage adjustments should be made in cases of severe liver toxicity and side effects, such as an increase in bilirubin exceeding the upper limit of the normal range or an increase in transaminases exceeding the upper limit of the normal range. The drug should be discontinued until the above indicators decrease respectively. to . or . times less than the upper limit of the normal range.
, )
, ) Dosage adjustment during neutropenia or thrombocytopenia during acceleration or blast phase if severe neutropenia and thrombocytopenia occur (neutrophils less than ./and/or If the platelet count is less than the recommended dose, reduce the dose to /day. If the blood cell count continues to decrease for weeks, the dose should be further reduced to /day. If the blood cell count continues to decrease for weeks, it is advisable to discontinue the drug until neutrophils./ and platelets/. When used again, the dose is /day .
, )
, ) It is advisable to discontinue the drug when the neutrophil count is less than ./ and/or the platelet count is less than/ in chronic phase patients after failure of interferon treatment. Only when the neutrophil count is ./ and the platelet count is less than/ When the medication is resumed, the dose is /day. If the neutrophils or platelets are reduced to the above values again, the dose is reduced to /day when the medication is resumed.
, )
, ) Dosage for patients with liver failure. The plasma concentration of imatinib mesylate may increase in patients with liver damage. Therefore, these patients should be cautious when using this drug. There is no hepatic disease. There are clinical data on the use of imatinib mesylate in patients with functional impairment, and no recommendations for dose adjustment can be made.
, )
, ) Dosage in patients with renal failure and elderly patients. Creatinine clearance is known to decrease with age, but age has no significant effect on the pharmacokinetics of imatinib mesylate. , as no clinical trials have been conducted in patients with renal impairment, dosage adjustment recommendations cannot be made.
Gleevec purchase phone number in India